Accenture invests in QuantHealth to accelerate AI use in drug development

Accenture announced it has made a strategic investment, through Accenture Ventures, in QuantHealth, an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients…With proprietary AI technology trained on a massive dataset of 350 million patients, large biomedical knowledge-graphs, and clinical trial data, QuantHealth’s simulation platform can predict trial outcomes with significant accuracy. It can test thousands of protocol variations and discover the optimal trial design for success, helping research and development eams more accurately and rapidly predict clinical trial results and decide whether a trial should proceed, how to optimize cohorts, whether drugs can be repurposed, and other crucial factors. “QuantHealth’s clinical trial simulation platform can fast-track clinical trials and help pharmaceutical and biotech companies bring life-saving treatments to patients” said Tom Lounibos, global lead of Accenture Ventures. “By accelerating and enhancing global drug discovery efforts, we’ll aim to work alongside QuantHealth, our clients and ecosystem partners to expand medicine and treatment options and find new opportunities to bolster patient care.”